Micromethods for the Measurement of Purine Enzymes in Lymphocytes

  • J. P. R. M. van Laarhoven
  • G. Th. Spierenburg
  • F. T. J. J. Oerlemans
  • C. H. M. M. de Bruyn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 122B)


The involvement of purine interconversion enzyme defects in impairment of the immune system is now well documented (1–3). Although it has been suggested that deoxypurine nucleotides might be the toxic metabolites in these immune diseases (4–5), the mechanism which leads to dysfunctions of T or B cells, or both of them, is still not completely elucidated. A better understanding of purine interconversions in B and T cell subfractions might help to obtain a better view on B or T cell specificity in these immune diseases. One of the possibilities to achieve this might be a systematic analysis of purine metabolism in T and non-T lymphocytes.


Purine Metabolism Immune Disease Purine Nucleoside Phosphorylase Disodium EDTA Adenine Phosphoribosyltransferase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E.R. Giblett, J.E. Anderson, F. Cohen, B. Pollara and H.J. Meuwissen, Lancet i:1067 (1972).CrossRefGoogle Scholar
  2. 2.
    E.R. Giblett, A.J. Ammann, D.W. Ward, R. Sandman and L.K. Diamond, Lancet ii:1010 (1975).CrossRefGoogle Scholar
  3. 3.
    N.L. Edwards, D.B. Magilavy, J.T. Cassidy and I.H. Fox, Science 201:628 (1975).CrossRefGoogle Scholar
  4. 4.
    D.A. Carson, J. Kaye and J.E. Seegmiller, Proc. Natl. Acad. Sci. USA, 74:5677 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    A. Cohen, L.J. Gudas, A.J. Ammann and G.E.J. Staal, J. Clin. Invest. 61:1405 (1977).CrossRefGoogle Scholar
  6. 6.
    P. Hösli, Tecnomara A.G., Rieterstrasse 59, Postfach CH 8059, Zürich, Switzerland (1972).Google Scholar
  7. 7.
    P. Hösli, in: Birth Defects, A. Motulsky and W. Lenz, eds., Exerpta Medica, Amsterdam, p. 226 (1974).Google Scholar
  8. 8.
    P. Hösli, Clin. Chem. 23:1476 (1977).PubMedGoogle Scholar
  9. 9.
    C.H.M.M. de Bruyn, T.L. Oei and P. Hösli, Biochem. Biophys. Res. Commun. 68:483 (1977).CrossRefGoogle Scholar
  10. 10.
    M.P. Uitendaal, C.H.M.M. de Bruyn, T.L. Oei, P. Hösli and C. Griscelli, Anal. Biochem. 84:147 (1978).PubMedCrossRefGoogle Scholar
  11. 11.
    M.P. Uitendaal, C.H.M.M. de Bruyn, T.L. Oei, S.J. Geerts and P. Hösli, Biochem. Med. 20:54 (1978).CrossRefGoogle Scholar
  12. 12.
    B.E.J de Pauw, J.M.C. Wessels, E.J.M. Geestman, J.B.J.M. Smeulders, D.J.Th. Wagener and C. Haanen, J. Imm. Meth. 25:291 (1979).CrossRefGoogle Scholar
  13. 13.
    O. H. Lowry, N.J. Rosebrough, A.L. Farr and R.J. Randall, J. Biol. Chem. 193:265 (1951).PubMedGoogle Scholar
  14. 14.
    F.L. Meyskens and H.E. Williams, Biochem. Biophys. Acta, 240:170 (1971).PubMedCrossRefGoogle Scholar
  15. 15.
    C. Ip and T. Dao, Cancer Res. 38:723 (1978).PubMedGoogle Scholar
  16. 16.
    J.P.R.M. van Laarhoven, G.Th. Spierenburg, C.H.M.M. de Bruyn and E.D.A.M. Schretlen, in preparation.Google Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • J. P. R. M. van Laarhoven
    • 1
  • G. Th. Spierenburg
    • 1
  • F. T. J. J. Oerlemans
    • 1
  • C. H. M. M. de Bruyn
    • 1
  1. 1.Department of Human Genetics, Faculty of MedicineUniversity of NijmegenNijmegenThe Netherlands

Personalised recommendations